These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 18227856)
21. [Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer]. Morote Robles J Actas Urol Esp; 1996 Jan; 20(1):1-12. PubMed ID: 8720993 [No Abstract] [Full Text] [Related]
22. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis]. Ohori M Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558 [TBL] [Abstract][Full Text] [Related]
23. Biomarkers for prostate cancer. Makarov DV; Loeb S; Getzenberg RH; Partin AW Annu Rev Med; 2009; 60():139-51. PubMed ID: 18947298 [TBL] [Abstract][Full Text] [Related]
24. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality. Höltl W; Lunglmayr G Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868 [No Abstract] [Full Text] [Related]
25. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. Etzioni RD; Ankerst DP; Weiss NS; Inoue LY; Thompson IM J Natl Cancer Inst; 2007 Oct; 99(20):1510-5. PubMed ID: 17925534 [TBL] [Abstract][Full Text] [Related]
26. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. Müller H; Haug U; Rothenbacher D; Stegmaier C; Brenner H J Urol; 2008 Oct; 180(4):1309-12; discussion 1312-3. PubMed ID: 18707695 [TBL] [Abstract][Full Text] [Related]
28. Prostate specific antigen testing for the diagnosis of prostate cancer. McKenzie P; Delahunt B; deVoss K; Ross B; Tran H; Sikaris K Pathology; 2011 Aug; 43(5):403. PubMed ID: 21753713 [No Abstract] [Full Text] [Related]
29. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. Byrne JC; Downes MR; O'Donoghue N; O'Keane C; O'Neill A; Fan Y; Fitzpatrick JM; Dunn M; Watson RW J Proteome Res; 2009 Feb; 8(2):942-57. PubMed ID: 19093873 [TBL] [Abstract][Full Text] [Related]
30. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175 [TBL] [Abstract][Full Text] [Related]
31. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. Flaig TW; Nordeen SK; Lucia MS; Harrison GS; Glodé LM J Urol; 2007 Apr; 177(4):1229-37. PubMed ID: 17382696 [TBL] [Abstract][Full Text] [Related]
32. Screening for prostate cancer in 2007: the PSA era and its challenges are not over. Shariat SF; Karakiewicz PI Eur Urol; 2008 Mar; 53(3):457-60. PubMed ID: 18079050 [No Abstract] [Full Text] [Related]
39. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed]. Bratt O; Björk T Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615 [No Abstract] [Full Text] [Related]
40. New markers and multivariate models for prostate cancer detection. Stephan C; Rittenhouse H; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K Anticancer Res; 2009 Jul; 29(7):2589-600. PubMed ID: 19596933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]